User profiles for "author:Robin Jones"

Robin Jones

ROYAL MARSDEN AND INSTITUE OF CANCER RESEARCH
Verified email at doctors.org.uk
Cited by 40323

[HTML][HTML] Raman techniques: fundamentals and frontiers

RR Jones, DC Hooper, L Zhang, D Wolverson… - Nanoscale research …, 2019 - Springer
Driven by applications in chemical sensing, biological imaging and material
characterisation, Raman spectroscopies are attracting growing interest from a variety of …

Treatment outcome with sex offenders

WL Marshall, R Jones, T Ward, P Johnston… - Clinical Psychology …, 1991 - Elsevier
Previous reviews have taken either a severe methodological stance and concluded that
treatments have not been demonstrated to be effective with sex offenders, or they have …

[HTML][HTML] The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients

B Alman, S Attia, C Baumgarten, C Benson… - European Journal of …, 2020 - Elsevier
Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis,
aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic …

[HTML][HTML] Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase …

GD Demetri, M Von Mehren, RL Jones… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or
Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III …

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

WD Tap, RL Jones, BA Van Tine, B Chmielowski… - The Lancet, 2016 - thelancet.com
Background Treatment with doxorubicin is a present standard of care for patients with
metastatic soft-tissue sarcoma and median overall survival for those treated is 12–16 …

[HTML][HTML] Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer… - Annals of oncology, 2022 - Elsevier
Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

F Grosso, RL Jones, GD Demetri, IR Judson… - The lancet …, 2007 - thelancet.com
Background Previous studies have suggested that trabectedin (ecteinascidin-743) could
have antitumour activity in soft-tissue sarcoma. We aimed to study the usefulness of …

[HTML][HTML] Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

A Fendler, STC Shepherd, L Au, KA Wilkinson, M Wu… - Nature cancer, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

DSP Tan, C Marchió, RL Jones, K Savage… - Breast cancer research …, 2008 - Springer
Background We analysed the clinical features, distribution of basal markers, prevalence of
oncogene amplification, and outcome of triple negative (TN) compared to those of non-TN …

Differential sensitivity of liposarcoma subtypes to chemotherapy

RL Jones, C Fisher, O Al-Muderis, IR Judson - European journal of cancer, 2005 - Elsevier
Liposarcoma is one of the most common soft tissue sarcomas and has a number of different
subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic …